Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Microsatellite Instability 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carboxylesterase × Lymphoid × Clear all
NCT04106167 2023-09-21

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Fate Therapeutics

Terminated
20 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡